https://scholars.lib.ntu.edu.tw/handle/123456789/551085
標題: | A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients | 作者: | CHEN-HUA LIU CHUN-JEN LIU CHUN-MING HONG TUNG-HUNG SU HUNG-CHIH YANG Chen K.-M Huang Y.-P Yeh Y.-M Tien H.-L Liu Y.-C JIA-HORNG KAO DING-SHINN CHEN PEI-JER CHEN |
公開日期: | 2018 | 出版社: | Blackwell Publishing | 卷: | 33 | 期: | 1 | 起(迄)頁: | 291-297 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Background and Aims: The diagnostic accuracy of a novel serological panel (BioFibroScore?) to predict hepatic fibrosis in patients with chronic hepatitis C virus (HCV) infection is unknown. Methods: Three markers of BioFibroScore, including urokinase plasminogen activator, matrix metalloproteinase-9, and beta-2 microglobulin, were retrospectively evaluated in 635 HCV-infected patients who received percutaneous liver biopsy and FibroScan?. The formula of BioFibroScore to predict the severity of hepatic fibrosis was developed by adaptive boosting algorithm. The diagnostic accuracy of hepatic fibrosis was assessed both for BioFibroScore and FibroScan, taking METAVIR fibrosis score as the reference standard. Results: Urokinase plasminogen activator and beta-2 microglobulin were positively and matrix metalloproteinase-9 was negatively associated with the severity of hepatic fibrosis. Thirty-five (5.5%) patients had failed FibroScan assessment. By adaptive boosting model for BioFibroScore and the established reference ranges for FibroScan, 85.7% and 89.0% of the patients had an identical result for F0-1, F2, F3, and F4, as compared with liver biopsy. The concordance rate between BioFibroScore and FibroScan was 80.7%. BioFibroScore overestimated and underestimated the stage of hepatic fibrosis in 8.3% and 6.0% patients, and most patients had one stage error. Among patients with failed FibroScan assessment, 82.9% of them were correctly diagnosed by BioFibroScore. Bootstrap analysis for BioFibroScore showed the diagnostic accuracy was 80.9–88.4%. Conclusions: BioFibroScore is accurate to assess the stage of hepatic fibrosis in HCV-infected patients. Applying this noninvasive test can substantially reduce the need for invasive liver biopsy and can play a role for fibrosis evaluation when FibroScan assessment was unavailable or unreliable. ? 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85039461203&doi=10.1111%2fjgh.13834&partnerID=40&md5=8b20a810a7898c29649df43ebe270dfa https://scholars.lib.ntu.edu.tw/handle/123456789/551085 |
ISSN: | 0815-9319 | DOI: | 10.1111/jgh.13834 | SDG/關鍵字: | beta 2 microglobulin; gelatinase B; urokinase; beta 2 microglobulin; biological marker; gelatinase B; urokinase; adult; algorithm; Article; bootstrapping; chronic hepatitis C; clinical evaluation; controlled study; correlation analysis; cross-sectional study; diagnostic accuracy; diagnostic test accuracy study; disease severity; female; human; human tissue; limit of quantitation; liver biopsy; liver fibrosis; logistic regression analysis; major clinical study; male; METAVIR score; middle aged; non invasive procedure; priority journal; protein blood level; receiver operating characteristic; retrospective study; scoring system; transient elastography; adolescent; aged; blood; chronic hepatitis C; complication; liver cirrhosis; predictive value; sensitivity and specificity; very elderly; young adult; Adolescent; Adult; Aged; Aged, 80 and over; beta 2-Microglobulin; Biomarkers; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Matrix Metalloproteinase 9; Middle Aged; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Urokinase-Type Plasminogen Activator; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。